

Received July 8, 2019, accepted September 30, 2019, date of publication October 11, 2019, date of current version November 5, 2019. Digital Object Identifier 10.1109/ACCESS.2019.2946905

# Estimation of Blood Oxygen Saturation in the Circulation Circuit for Extracorporeal Membrane Oxygenation

# KAZUYA NAKANO<sup>®</sup><sup>1</sup>, MAKOTO ADACHI<sup>2</sup>, TAKASHI OHNISHI<sup>®</sup><sup>1</sup>, YUTAKA FURUKAWA<sup>3</sup>, TAKA-AKI NAKADA<sup>4</sup>, SHIGETO ODA<sup>4</sup>, AND HIDEAKI HANEISHI<sup>1</sup>

<sup>1</sup>Center for Frontier Medical Engineering, Chiba University, Chiba 263-8522, Japan
<sup>2</sup>Graduate School of Science and Engineering, Chiba University, Chiba 263-8522, Japan

<sup>3</sup>Chiba University Hospital, Chiba 260-8677, Japan

<sup>4</sup>Graduate School of Medicine, Emergency and Critical Care Medicine, Chiba University, Chiba 260-8677, Japan

Corresponding author: Kazuya Nakano (knakano@chiba-u.jp)

This work was supported in part by JSPS Core-to-Core Program.

**ABSTRACT** Extracorporeal membrane oxygenation (ECMO) is a treatment that supports heart and lung functions with a circulation circuit external to the body. In ECMO, it is important to monitor blood oxygen saturation (SO<sub>2</sub>) in the circulation tube. As a means of continuous SO<sub>2</sub> measuring, a special connector is inserted into the circuit. However, this method is unsuitable for emergency treatment. Therefore, it is necessary to measure blood SO<sub>2</sub> in the tube without the connector. However, this creates problems for SO<sub>2</sub> estimation, due to varying blood concentration and flow velocity, hemolysis, and wall thickness of the tube. Therefore, we developed a SO<sub>2</sub> estimation method that can calibrate the variation in blood concentration. The method is based on a conversion model between absorbance and SO<sub>2</sub> (CAS), which varies depending on the concentration. In this method, the CAS for the SO<sub>2</sub> estimation is estimated by CAS corresponding to two blood samples prepared in advance with different concentrations. The experiment for SO<sub>2</sub> estimation was conducted with a spectroscope, a halogen light source, and a cut tube. We confirmed that the average error of estimated SO<sub>2</sub> against the SO<sub>2</sub> values measured by a gas analysis was 3.8% within a blood volume concentration range from 50 to 90%. In future work, to improve the estimation accuracy, we will improve our method by investigating other factors that may affect the accuracy.

**INDEX TERMS** Biomedical monitoring, spectroscopy, circulators.

#### I. INTRODUCTION

### A. EXTRACORPOREAL MEMBRANE OXYGENATION

Extracorporeal membrane oxygenation (ECMO) has been employed for patients who need support for heart and lung function (e.g., heart failure or lung transplant) since 1971 [1]. An ECMO system mainly consists of circulation tubes, an artificial pump, and an artificial lung external to the body. In this system, venous blood is extracorporeally withdrawn from a patient through a catheter placed in the vena cava and blood flow is generated by the centrifugal pump. After the blood is oxygenated and decarboxylated by the artificial lung, it is returned to the patient. When the blood flows though the artificial lung, the  $O_2$  and  $CO_2$  of the blood by

The associate editor coordinating the review of this manuscript and approving it for publication was Jenny Mahoney.

the semipermeable membrane are exchanged. To ensure sufficient oxygen supply during ECMO treatment, it is necessary to monitor the patient's venous oxygen saturation (SO<sub>2</sub>). Currently, two methods are typically used to monitor the SO<sub>2</sub> in ECMO.

One method is to measure the  $SO_2$  of blood sampled from the tube using blood gas analysis. This method can measure  $SO_2$  with high accuracy. However, it is not practical to sample blood repeatedly for continuous monitoring of  $SO_2$ . Moreover, withdrawing blood samples from the tube increases the risk of medical accident, such as the mixing of air bubbles in blood, infection, and leakage of blood. The other method is to estimate  $SO_2$  from the reflected light intensity measured through a connector that works as a transparent cuvette for optical measurement. To use this connector, it must be installed in the extracorporeal circulation circuit. However,

in some cases, ECMO treatment is started without setting this connector, usually during emergencies, when medical staff may not have enough time to connect it in the ECMO circuit. This is because the connection procedure is difficult to perform without leakage when the blood flow pressure is high. In addition, preparation for the connection requires sterilization of both the connector and the hands. When ECMO is immediately needed, an increase in the preparation time leads to high patient mortality. Furthermore, smaller hospitals do not always stock the connector because the ECMO system is used infrequently. Another disadvantage in using the connector is that it may cause infection or blood coagulation. Therefore, inserting additional parts into the circuit is not preferable. Some products incorporate the connector into the circuit in advance, which may solve these problems. However, simple products without the special circuit are still widely used because it can be started quickly.

To estimate SO<sub>2</sub> in blood vessels, various estimation methods have been used. A pulse oximeter has been used to estimate arterial  $SO_2$  in clinical fields [2]–[4]. However, a pulse oximeter, which requires the detection of a pulse wave, cannot be used in ECMO systems because they employ a centrifugal pump, which produces no pulse wave in the ECMO circuit. Recently, near-infrared (NIR) spectroscopy has also been used to measure regional SO<sub>2</sub> of cerebral blood [5], [6]. Moreover, there are many NIR-based tissue oximeters, for example, NIRO-200NX (Hamamatsu Photonics K.K., Shizuoka, Japan), FORE-SIGHT ELITE (CAS Medical Systems Inc., Branford, CT, USA), SenSmart-X100 (Nonin Medical Inc., Plymouth, MN, USA), OxiplexTS (ISS Inc., Champaign, IL, USA), INVOS 5100C (Medtronic plc, Dublin, Ireland), and OxyPrem (OxyPrem AG, Zurich, Switzerland). Kleiser et al. compared the SO<sub>2</sub> values measured from the same phantom using these products and reported that the values varied among them [7]. Furthermore, when the measurement point was changed, the SO<sub>2</sub> value also changed. Therefore, these products are not applicable for monitoring SO<sub>2</sub> in ECMO because the SO<sub>2</sub> value estimated from these products has low reliability in this application. For these reasons, it is desirable that the SO<sub>2</sub> be directly estimated in the ECMO circuit tube without a connector. Thus, this study developed a method for estimating blood SO<sub>2</sub> in an ECMO tube without the connector. Our study will contribute to the monitoring of blood SO2 during ECMO treatment quickly and safely.

## B. PROBLEMS IN SO<sub>2</sub> ESTIMATION

We estimated the blood  $SO_2$  in an ECMO tube using absorbance analysis. Compared to tissue oximeters, the estimation of blood  $SO_2$  in a tube seems to be easier than estimation in tissue because tissue composition is more complex. However, there are also some problems for the estimation within the ECMO circuit, caused by, for example, blood concentration, blood flow velocity, hemolysis, and wall thickness of the tube. Especially, because infusion is administered to a patient for enhancing circulation during ECMO treatment,



FIGURE 1. Molar extinction coefficients of HbO<sub>2</sub> and Hb.

the blood concentration can rapidly and significantly vary. This leads to changes in light absorption and scattering, which affects SO<sub>2</sub> estimation. In addition, the blood flow velocity in the circulation tube is adjusted depending on the variation of oxygen supply quantity during the treatment. Thus, when the number of red cells per unit time and the orientation of the cells vary by changing the velocity, this also leads to a change in blood light properties. Especially, because red blood cells are disk shaped with the center recessed inward, their orientation affects the light scattering. Moreover, light transmission is changed by hemolysis as red cells are destroyed by the ECMO pump and internal tube pressure. These factors affect the estimation of blood SO<sub>2</sub> in an ECMO system. In this study, we focused on the blood concentration and analyzed the relationship between the blood concentration and absorbance. In addition, we developed a calibration method for SO<sub>2</sub> estimation. The detailed analysis and estimation process are described in the following sections.

## **II. ESTIMATION METHODS**

## A. ESTIMATION PRINCIPLE

The main light absorbers in the human blood are oxyhemoglobin (HbO<sub>2</sub>) and deoxy-hemoglobin (Hb). Therefore, blood SO<sub>2</sub> is defined as the ratio of HbO<sub>2</sub> concentration to the total Hb concentration. Blood SO<sub>2</sub> can be estimated by measuring the blood absorbance because Hb and HbO<sub>2</sub> have different optical properties [8], as shown in Fig. 1. Absorbance  $A(\lambda)$  is defined as

$$A(\lambda) = -\log T(\lambda) = -\log \frac{I_{\text{out}}(\lambda)}{I_{\text{in}}(\lambda)},$$
 (1)

where  $I_{in}(\lambda)$  and  $I_{out}(\lambda)$  describe the intensities of incident and transmitted light, respectively.

In addition, absorbance  $A(\lambda)$  can be expressed based on Lambert-Beer's law as follows:

$$A(\lambda) = \left[\varepsilon_{\text{HbO}_2}(\lambda) C_{\text{HbO}_2} + \varepsilon_{\text{Hb}}(\lambda) C_{\text{Hb}}\right] l, \qquad (2)$$

where l,  $\varepsilon(\lambda)$ , and C denote the path length of the transmitted light, the molar extinction coefficient, and the molar concentration, respectively. In addition, SO<sub>2</sub> is expressed by



**FIGURE 2.** Relationship between blood absorbance and SO<sub>2</sub> obtained by spectroscope and blood gas analyzer.

Hb concentration as

$$s = \frac{C_{\text{HbO}_2}}{C_{\text{HbO}_2} + C_{\text{Hb}}} \times 100, \tag{3}$$

where *s* denotes  $SO_2$ . From (2) and (3), the relationship between  $SO_2$  and the absorbance can be expressed based on Lambert-Beer's law by

$$A (\lambda) = \left[ \varepsilon_{\text{HbO}_2} (\lambda) SO_2 + \varepsilon_{\text{Hb}} (\lambda) (1 - SO_2) \right] C_{\text{HbT}} \cdot l,$$
  

$$C_{\text{HbT}} = C_{\text{Hb}} + C_{\text{HbO}_2},$$
(4)

where  $C_{\text{HbT}}$  denotes total Hb concentration. If the path length *l* is constant, the absorbance can be expressed by linearly combining the substances' molar extinction coefficients. Therefore, SO<sub>2</sub> can be estimated by solving a simple linear regression problem [9]. However, in reality, the path length *l* is not constant due to light scattering, and it must be defined as the optical path length function of the wavelength. Fig. 2 shows the relationship between SO<sub>2</sub> and absorbance that were measured using a blood gas analyzer (i-STAT Analyzer 300F, Abbott Point of Care, Princeton, NJ, USA). As shown in Fig. 2, the relationship is nonlinear and is not based on Lambert-Beer's law. For this reason, it is difficult to estimate the blood SO<sub>2</sub> in an ECMO tube based on (2).

A previous study proposed a SO<sub>2</sub> estimation method based on a conversion model between absorbance and SO<sub>2</sub> (CAS) [10]. CAS is given by the conversion table that is created by sets of the known blood SO<sub>2</sub> and measured absorbance of the blood. As long as the blood concentration and measuring environment do not change, CAS is effective as a method in consideration of the scattering and wavelength dependency of the path length. However, the estimation accuracy of CAS decreases when the blood concentration or the measuring environment changes. Hence, we propose a CAS correction method using two types of CAS, which are calculated in the preparation step.

#### **B. PROPOSED METHOD FOR ESTIMATING SO<sub>2</sub>**

First, we describe the basic concept of the proposed method to estimate  $SO_2$  in response to various blood concentrations. However, it is difficult to prepare a table for the calibration



**FIGURE 3.** Absorbance data required for estimating blood SO<sub>2</sub> in ECMO tube.



**FIGURE 4.** Overview of preparation step. Absorbance values of blood with various SO<sub>2</sub> and two types of concentration were obtained. CASP<sub>h</sub> and CASP<sub>l</sub> were then acquired by an approximating function.

of the blood concentration in advance, because we must measure many blood samples by changing blood concentration and SO<sub>2</sub> within a wide range. Therefore, in our method, we used two types of CAS based on the approximation functions between absorbance and SO<sub>2</sub>. The functions are calculated from data obtained from two blood samples with high or low blood concentration. The two types of CAS for the preparation are defined as  $CASP_h$  and  $CASP_l$  for high and low concentrations, respectively. Fig. 3 shows the data for both CAS preparations with respect to both SO<sub>2</sub> and blood concentration. As shown in Fig. 3, the data reflecting high blood concentration are used to obtain  $CASP_h$ , whereas those reflecting low blood concentration are used to obtain CASP<sub>1</sub>. The two concentrations are determined so as to satisfy the assumed range of the concentration during ECMO treatment. The  $SO_2$  of arbitrary blood concentration between  $CASP_h$ and  $CASP_l$  is estimated from model-based approximation. Next, we explain the procedures of our method in detail.

The proposed estimation method has two steps, a preparation step and an estimation step. Fig. 4 shows the preparation step that is intended to be conducted in the manufacturing process. In this step, we obtain  $CASP_h$  and  $CASP_l$ . Although CASP requires a large amount of data, this process is expected to be completed before clinical application.

In the first process, the absorbance of the blood with respect to  $SO_2$  is measured by two wavelengths. As illustrated in Fig. 3, the absorbance data are obtained by changing the  $SO_2$ . The two types of blood concentrations, high and low, are preferably set so that the assumed range of blood concentration can be covered. Measurement with narrow  $SO_2$  intervals is desirable because CASP is obtained by approximating the relationship between  $SO_2$  and absorbance. After measuring



**FIGURE 5.** Overview of estimation step. (a) Blood concentration calibration, (b) estimation process of  $SO_2$  using CASE. The blood absorbance with 100%  $SO_2$  is acquired at the outflow tube. CASE is then generated by CASP<sub>h</sub>, CASP<sub>l</sub> (two solid curves), and the acquired absorbance (dashed curve). The blood absorbance is obtained at the inflow tube, and  $SO_2$  is estimated with this absorbance and CASE.

the blood absorbance, CASP<sub>h</sub> and CASP<sub>l</sub> were calculated. In our method, absorbance  $A'_{\lambda_1,\lambda_2}(s)$  with two wavelengths  $\lambda_1$  and  $\lambda_2$  for CAS was calculated as

$$A'_{\lambda_1,\lambda_2}(s) = \frac{A_{\lambda_1}(s) + d}{A_{\lambda_2}(s) + d},$$
(5)

where d denotes an arbitrary constant value. This absorbance shows the ratio between the absorbance with two wavelengths and was used to enhance the influence of SO<sub>2</sub>. If the proper wavelengths are set, when SO<sub>2</sub> changes, the absorbance of the numerator increases or decreases, whereas that of the denominator decreases or increases. In this study, two wavelengths, 663 nm and 933 nm, were selected because the SO<sub>2</sub> error that was estimated using these wavelengths was the smallest when SO<sub>2</sub> was estimated by selecting two wavelengths at 1 nm intervals from 650 nm to 950 nm. Furthermore, to prevent the denominator from being negative, d was determined. Thus, the optimal d varies depending on the wavelength selection and we set d = -1.1 in this study. After calculation of (5), we acquired the CASP (s) approximation with a function including an exponent by

$$A'_{\lambda_1,\lambda_2}(s) = \text{CASP}(s) = \alpha e^{\beta s} + \gamma.$$
(6)

From (6),  $CASP_h(s)$  and  $CASP_l(s)$  were obtained.

Fig. 5 shows the estimation step that is intended to be conducted during ECMO treatment. CAS is estimated by employing the CASP generated in the preparation step. The CAS for estimation is defined as CASE. Finally, we can acquire the SO<sub>2</sub> of the blood by applying this CASE. First, the absorbance of the blood flow that was oxygenated through the artificial lung was measured with two wavelengths. We assumed that the SO<sub>2</sub> of the blood is 100% after it passes through the artificial lung and the blood concentration does not vary before and after the artificial lung. Although the absorbance varies depending on blood concentration, our method enables calibration of the blood concentration. In this



FIGURE 6. Relationship of CASP<sub>h</sub>, CASP<sub>l</sub>, and CASE.

step, CASE is expressed with  $CASP_h(s)$  and  $CASP_l(s)$  as follows:

$$A'_{\lambda_1,\lambda_2}(s) = \text{CASE}(s)$$
  
=  $r_h(s) \text{CASP}_h(s) + r_l(s) \text{CASP}_l(s)$ , (7)

where  $r_h(s)$  and  $r_l(s)$  represent the ratio of CASE(s) between the two types of CASP. As shown in Fig. 6, these ratios were calculated by

$$r_{h}(s) = \frac{|\text{CASE}(s) - \text{CASP}_{h}(s)|}{|\text{CASP}_{h}(s) - \text{CASP}_{l}(s)|},$$
(8)

$$r_l(s) = \frac{|\text{CASE}(s) - \text{CASP}_l(s)|}{|\text{CASP}_h(s) - \text{CASP}_l(s)|}.$$
(9)

We assumed that  $r_h(s)$  and  $r_l(s)$  do not depend on *s* under the condition of constant blood concentration. Therefore, (7) could be rewritten based on this assumption as follows:

$$r_h(s) = r_h(100), \ r_l(s) = r_l(100),$$
 (10)  
 $A'_{\lambda_1,\lambda_2}(s) = \text{CASE}(s)$ 

$$= r_h (100) \operatorname{CASP}_h (s) + r_l (100) \operatorname{CASP}_l (s). \quad (11)$$

The ratios  $r_h$  (100) and  $r_l$  (100) were calculated by (8) and (9), respectively. CASE(100) was calculated by measuring the absorbance of the blood passed from the artificial lung. Therefore, after calculating these ratios, the calibrated CASE(*s*) was calculated by (11). Therefore, even if the blood concentration is unknown during ECMO treatment, CASE(*s*) can be calibrated by both CASP<sub>h</sub>(*s*) and CASP<sub>l</sub>(*s*) obtained in the preparation step. Finally, as shown in Fig. 5(b), the estimated value  $\hat{s}$  of SO<sub>2</sub> was calculated with the measured absorbance  $A'_{\lambda_1,\lambda_2}$  before the oxygenation and the inverse function CASE<sup>-1</sup>(*s*) by

$$\hat{s} = \text{CASE}^{-1} \left( A'_{\lambda_1, \lambda_2} \right). \tag{12}$$

## **III. EXPERIMENTS**

#### A. BLOOD PREPARATION

In our experiments, bovine blood was selected for circulation in an ECMO tube. To prevent the blood from clotting, sodium citrate and heparin sodium were added to the blood as anticoagulant. To prepare blood samples with various concentrations, the blood samples were diluted by saline for volume concentrations (VCs) from 40% to 100% in 10%



FIGURE 7. Relative intensity of halogen light.



**FIGURE 8.** Measurement environment of blood absorbance, (a) overall view and (b) top view with size of tube.

intervals. The SO<sub>2</sub> of the blood was changed with air stirring for oxygenation and mixing with sodium hypochlorite for deoxygenation between 0% and 100%. Both the Hb concentration and SO<sub>2</sub> of the prepared blood samples were measured by a blood gas analyzer (i-STAT Analyzer 300F, Abbott Point of Care, Princeton, NJ, USA). The average Hb concentration of 100% VC was 10.6 g/dl. The SO<sub>2</sub> of the blood was changed from 0% to 100%. Moreover, the VC was also changed in 10% increments from 40% to 100%. First, to calculate CASP<sub>h</sub> and CASP<sub>l</sub>, the data with 40% and 100% VCs were used in the preparation step. Next, to calculate both  $r_h$  (100) and  $r_l$  (100), the data corresponding to 100% SO<sub>2</sub> were used. After obtaining the result for (11), the remaining data were used for the evaluation of our method.

## **B. ABSORBANCE MEASUREMENT**

To calculate the blood absorbance in an ECMO tube (CAPIOX custom pack, TERUMO Corp., Tokyo, Japan), the transmitted light intensity was measured using a spectroscope (USB Flame, Ocean Optics Inc., FL, USA) and a halogen light source (MHF-G150LR, MORITEX Corp., Saitama, Japan). We used a spectroscope as light detector. Fig.7 shows the relative intensity of the light source that was measured using the spectroscope. The spectroscope was used to examine many combinations of two wavelengths. Fig. 8 shows the experimental conditions for the measurement. The length of the cut tube shown in Fig. 8(a) was 4.7 cm. The internal diameter and wall thickness of the tube were 9.0 mm and 2.0 mm, respectively. To prevent the spectrometer and light source from interfering with each other, these devices were offset vertically. Moreover, the transmitted light and the dark current were measured in a dark room. After water was



FIGURE 9. Obtained blood absorbance for various VC and SO<sub>2</sub> values at each wavelength, (a) 663 nm and (b) 933 nm.

**TABLE 1.** Approximation error of CASPs corresponding to 100% VC and 40% VC (error, Eso<sub>2</sub>, was calculated in the ranges of 0–100%, 0–60%, and 60–100% SO<sub>2</sub>).

CASP (VC)	$E_{\mathrm{SO}_2}$ (%)	$E_{\mathrm{SO}_2}$ (%)	$E_{\mathrm{SO}_2}$ (%)
	(SO <sub>2</sub> : 0–100)	(SO <sub>2</sub> : 0–60)	(SO <sub>2</sub> : 60–100)
CASP <sub>h</sub> (100%)	5.1	7.2	1.8
CASP/(40%)	0.92	0.67	1.1

TABLE 2. Error evaluation of SO<sub>2</sub> estimation for each blood VC.

VC (%)	Average error	Maximum error	Standard deviation (%)
50-90	3.8	12	3.1
90	2.7	4.5	1.3
80	4.7	9.5	3.5
70	2.3	5.4	1.9
60	5.5	12	3.7
50	2.7	6.3	2.3

poured into the tube, the light intensity transmitted through the tube was also measured instead of the light incident on the blood. The blood absorbance was calculated by

$$A(\lambda) = -\log \frac{I_{\text{blood}}(\lambda) - I_{\text{dark}}(\lambda)}{I_{\text{water}}(\lambda) - I_{\text{dark}}(\lambda)},$$
(13)

where  $I_{blood}(\lambda)$ ,  $I_{water}(\lambda)$ , and  $I_{dark}(\lambda)$  are the light intensity transmitted through blood, water, and dark current, respectively.

## **IV. RESULTS AND DISCUSSION**

Fig. 9 shows the change in the absorbance  $A(\lambda)$  of the blood as the SO<sub>2</sub> and VC of the blood were changed. Fig. 9(a) and (b) shows the results for 663 nm and 933 nm, respectively. The absorbance at 663 nm decreased with the increase of SO<sub>2</sub>, whereas that of 933 nm increased. This result can be explained with the molar extinction coefficient of Hb (Fig. 1) as follows. From Fig. 1, the light absorption of Hb at 663 nm is stronger than that of HbO<sub>2</sub>. Thus, the absorbance decreased as SO<sub>2</sub> increased. In contrast, the light absorption of Hb. Therefore, the absorbance became higher gradually as SO<sub>2</sub> increased as VC decreased. This is because the light absorption became weak as the Hb concentration decreased.

TABLE 3. SO<sub>2</sub> estimation error for each range of blood SO<sub>2</sub>.





**FIGURE 10.** Acquired CASP<sub>h</sub> from 100% VC and CASP<sub>l</sub> from 40% VC. Red and blue symbols indicate measured absorbance data. Red and blue curves are the CASPs extrapolated from the measurement points.

In this experiment, the relationship between  $SO_2$  and the absorbance, especially in Fig. 9(a), was nonlinear, similar to that shown in Fig. 2, which gives us measurement results from the blood gas analyzer. In addition, as shown in Fig. 9, some absorbance data were negative. The data showed that the light intensity transmitted through water was higher than that transmitted through blood. Light absorption by Hb is stronger than that by water. However, because the spectroscope was set above the light source against the tube in our experiment, the detected light was not a straight beam from the light source, but rather bent light. When the light absorption by the Hb was strong, the absorbance had a positive value because the light intensity transmitted through the blood is much weaker than that of water. Conversely, when the light absorption by Hb was weak, we assumed that light intensity scattered by Hb was stronger than the light transmitted through water. As a result, the absorbance became negative. However, as discussed above, even if the absorbance becomes negative, CASPs can be calculated by (5).

Fig. 10 shows the  $CASP_h$  and  $CASP_l$  estimated in the preparation step. Although the two types of CASPs had similar values from 0% to 70%, they showed different tendencies as SO<sub>2</sub> increased. These CASP functions were obtained by making the measured data fit (5) as follows:

$$CASP_h(s) = 0.0764e^{0.0319s} + 0.178,$$
 (14)

$$CASP_l(s) = 0.169e^{0.0226s} + 0.0462.$$
(15)

Herein, the approximation accuracy of CASPs shown in Fig. 10 between the estimated  $SO_2$  values and the  $SO_2$ values measured by the gas analyzer was calculated by

$$E_{\text{so}_2} = \frac{1}{N} \sum_{i=1}^{N} \left| s_i - \text{CASP}^{-1}(x_i) \right|, \quad (16)$$



FIGURE 11. Result of SO<sub>2</sub> estimation for blood for various VC values, (a) 90%, (b) 80%, (c) 70%, (d) 60%, (e) 50%, (f) 50–90%.

where  $s_i$  is the SO<sub>2</sub> value measured by the gas analyzer of the *i*-th blood absorbance datum and  $x_i$  is the SO<sub>2</sub> value estimated from *i*-th absorbance datum. Table 1 shows the SO<sub>2</sub> errors for both CASPs. These values indicate the influence of the approximation error for SO<sub>2</sub> estimation. The average SO<sub>2</sub> errors by CASP<sub>h</sub>(VC=100%) and CASP<sub>l</sub>(VC=40%) estimation were 5.1% and 0.92%, respectively. In addition, from the results of CASP<sub>h</sub>, the approximation error in the SO<sub>2</sub> range of 0–60% was higher than that in the range of 60–100%. As discussed above, the light absorption by Hb at 663 nm is strong. Thus, when VC is high and SO<sub>2</sub> is low, the measured light intensity through the blood was low and affected by noise.

Fig. 11 shows the results of SO<sub>2</sub> estimation. Tables 2 and 3 show the estimation error of SO<sub>2</sub> for each blood VC and each SO<sub>2</sub>, respectively. In Table 2, it is seen that the average error was 3.8% within the VC range of 50% to 90%. In addition, the maximum error and standard deviation were 12% and 3.1%, respectively. Moreover, the average errors were all less than 5.5% for all VC values. Table 3 shows that the average error of data in the low range of SO<sub>2</sub>, 0–60%, is higher than that of data in the high range, 60–100%. As shown in Table 1, the results were due to stronger light absorption by Hb. Moreover, all average errors were less than 4.1% for both ranges of SO<sub>2</sub>.

#### V. CONCLUSION

In the present study, we developed a method that can robustly estimate the  $SO_2$  of blood in a tube, such as used in an ECMO circulation circuit, regardless of changes in blood concentration. In this study, to evaluate our method, blood absorbance was measured under conditions with various blood concentrations and  $SO_2$  values. The  $SO_2$  estimation is based on the CAS. First, in the preparation step, we prepared two blood samples having different concentrations and varied the blood SO<sub>2</sub>. After pouring each blood sample into the tube, the absorbance of the blood in the tube was measured using a spectroscope and halogen light source. After we obtained two functions between absorbance and SO<sub>2</sub>, which were defined as CASP, we obtained CASE to estimate the blood SO<sub>2</sub> in the ECMO tube by employing CASPs for blood VC calibration. Our SO<sub>2</sub> estimation method shows 3.8% average error within a blood VC range from 50 to 90%. Moreover, all average errors were also less than 5.5% for all values of VC: 50%, 60%, 70%, 80%, 90%, and 50-90%. Therefore, we confirmed that our method could estimate SO<sub>2</sub> in a tube with the stated accuracy. In future work, to achieve higher estimation accuracy, we will investigate the factors that may affect it, such as the thickness of the tube wall, blood flow, hemolysis, humidity, temperature, and cholesterol. Moreover, we will compare the results between our method and state of the art ECMO systems. We will improve our method using further investigation and prepare it for clinical use.

## REFERENCES

- P. J. Wolfson, "The development and use of extracorporeal membrane oxygenation in neonates," *Ann. Thoracic Surg.*, vol. 76, no. 6, pp. S2224–S2229, Dec. 2003.
- [2] K. K. Tremper, "Pulse oximetry," CHEST, vol. 95, no. 4, pp. 713–715, Apr. 1989.
- [3] J. E. Sinex, "Pulse oximetry: Principles and limitations," Amer. J. Emergency Med., vol. 17, no. 1, pp. 59–66, Jan. 1999.
- [4] A. Jubran, "Pulse oximetry," Crit. Care, vol. 19, pp. 1–7, Jul. 2015, Art. no. 272. [Online]. Available: https://ccforum.biomedcentral.com/ articles/10.1186/s13054-015-0984-8
- [5] A. Halevy, Z. Halpern, M. Negri, G. Hod, J. Weissgarten, Z. Averbukh, and D. Modai, "Pulse oximetry in the evaluation of the painful hand after arteriovenous fistula creation," *J. Vascular Surg.*, vol. 14, no. 4, pp. 537–539, Oct. 1991.
- [6] H. L. Edmonds, "Multi-modality neurophysiologic monitoring for cardiac surgery," *Heart Surg. Forum*, vol. 5, no. 3, pp. 225–228, Feb. 2002.
- [7] S. Kleiser, D. Ostojic, B. Andresen, N. Nasseri, H. Isler, F. Scholkmann, T. Karen, G. Greisen, and M. Wolf, "Comparison of tissue oximeters on a liquid phantom with adjustable optical properties: An extension," *Biomed. Opt. Express*, vol. 9, no. 1, pp. 86–101, Sep. 2018.
- [8] S. A. Prahl. (Dec. 15, 1999). Optical Absorption of Hemoglobin. Accessed: Jun. 25, 2018. [Online]. Available: http://omlc.org/spectra/ hemoglobin/summary.html
- [9] Y. Minami, T. Ohnishi, H. Kawahira, and H. Haneishi, "Fundamental study on intraoperative quantification of gastrointestinal viability by transmission light intensity analysis," in *Proc. ICISP*, in Lecture Notes in Computer Science, vol. 8509. Cherbourg-Octeville, France: IUT Cherbourg Manche, Jun. 2014, pp. 72–78.
- [10] J. M. Schmitt, F. G. Mihm, and J. D. Meindl, "New methods for whole blood oximetry," Ann. Biomed. Eng., vol. 14, no. 1, pp. 35–52, Jun. 1986.



**KAZUYA NAKANO** received the M.S. and Ph.D. degrees from the Tokyo Institute of Technology, Japan, in 2007 and 2013, respectively. He was with the Mizuho Information & Research Institute (MHIR), from 2007 to 2009. He was an Assistant Professor with Nippon Sport Science University, from 2013 to 2014 and also with the Tokyo University of Science, from 2015 to 2016. Since 2017, he has been an Assistant Professor with the Center for Frontier Medical Engineering, Chiba University is the Mitter of the Medical Engineering.

sity. His current research interests include diffuse reflectance spectroscopy, optical security, information photonics, and applied physics.



**MAKOTO ADACHI** received the B.S. and M.S. degrees in engineering from Chiba University, in 2017 and 2019, respectively. His current research interest includes oximetry.



**TAKASHI OHNISHI** received the M.S. and Ph.D. degrees from Chiba University, Japan, in 2010 and 2013, respectively. He is currently an Assistant Professor with the Center for Frontier Medical Engineering, Chiba University. His current research interests include image processing, image registration, and pathological images.



**YUTAKA FURUKAWA** received the B.Eng. degree from the Department of Mechanical Engineering, Tokyo Denki University, in 2001. He trained at the Yomiuri College, Tokyo for Clinical Engineering, from 2005 to 2007. Since 2007, he has been a Clinical Engineer with Chiba University Hospital.



**TAKA-AKI NAKADA** received the M.D. and Ph.D. degrees from Chiba University, Japan, in 1999 and 2006, respectively. He was a Postdoctoral Fellow with The University of British Columbia, Canada, from 2008 to 2011. He is currently an Associate Professor with the Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University.



**SHIGETO ODA** received the M.D. degree from the School of Medicine, Chiba University, in 1978, and the Ph.D. degree from the Graduate School of Medicine, Chiba University, in 1992. He joined the Department of Emergency and Critical Care Medicine, in 1988, where he has been a Professor and the Chairman, since 2006. He is currently a Professor with the Emeritus of Chiba University.



**HIDEAKI HANEISHI** received the M.S. and Ph.D. degrees from the Tokyo Institute of Technology, in 1987 and 1990, respectively. In 1990, he joined Chiba University as a Research Associate. He was a Visiting Research Scientist with the Department of Radiology, The University of Arizona, from 1995 to 1996. Since 2007, he has been a Full Professor with the Center for Frontier Medical Engineering (CFME), where he is also currently the Director.